Stephen P Jung

PTC725, an NS4B-Targeting Compound, Inhibits a Hepatitis C Virus Genotype 3 Replicon, as Predicted by Genome Sequence Analysis and Determined Experimentally

X. Tong, Z. Gu, F. Lahser, 2016, Antimicrobial Agents and Chemotherapy.

Identification of PTC725, an Orally Bioavailable Small Molecule That Selectively Targets the Hepatitis C Virus NS4B Protein

S. Peltz, X. Tong, Z. Gu, 2013, Antimicrobial Agents and Chemotherapy.

Discovery of 2-(4-sulfonamidophenyl)-indole 3-carboxamides as potent and selective inhibitors with broad hepatitis C virus genotype activity targeting HCV NS4B.

Z. Gu, A. Nomeir, F. Lahser, 2016, Bioorganic & medicinal chemistry letters.

Development of an oral treatment that rescues gait ataxia and retinal degeneration in a phenotypic mouse model of familial dysautonomia

S. Slaugenhaupt, J. Narasimhan, A. Mollin, 2023, American journal of human genetics.

6-(Azaindol-2-yl)pyridine-3-sulfonamides as potent and selective inhibitors targeting hepatitis C virus NS4B.

Z. Gu, H. Ren, A. Nomeir, 2015, Bioorganic & medicinal chemistry letters.

Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.

Ramesh Kakarla, Guangming Chen, Song Huang, 2014, Journal of medicinal chemistry.

Inhibiting expression of specific genes in mammalian cells with 5′ end-mutated U1 small nuclear RNAs targeted to terminal exons of pre-mRNA

J. Prieto, D. Rowe, P. Fortes, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Requirements for gene silencing mediated by U1 snRNA binding to a target sequence

P. Fortes, S. Gunderson, Stephen P Jung, 2008, Nucleic acids research.